Devices and methods for the treatment of heart failure

Abstract
A device for treating heart failure in a patient. The device comprising a body, at least one passage through the body, at least one one way valve in the passage and a mounting means adapted for mounting the body in an opening provided in the patient's atrial septum. In use, the device is oriented such that, when the patient's left atrial pressure exceeds the patient's right atrial pressure by a predetermined amount, the one way valve(s) opens to allow blood flow through the passage(s) from the left atrium to the right atrium to thereby reduce the left atrial pressure.
Description
FIELD OF THE INVENTION

The present invention relates generally to devices and methods for the treatment of heart failure and, more particularly, to devices and methods for the relief of high pressure in the cardiovascular system to alleviate symptoms of cardiovascular disease.


BACKGROUND OF THE INVENTION

Heart failure is a common and potentially lethal condition affecting humans, with sub-optimal clinical outcomes often resulting in symptoms, morbidity and/or mortality, despite maximal medical treatment. In particular, “diastolic heart failure” refers to the clinical syndrome of heart failure occurring in the context of preserved left ventricular systolic function (ejection fraction) and in the absence of major valvular disease. This condition is characterised by a stiff left ventricle with decreased compliance and impaired relaxation, which leads to increased end-diastolic pressure. Approximately one third of patients with heart failure have diastolic heart failure and there are very few, if any, proven effective treatments.


Symptoms of diastolic heart failure are due, at least in a large part, to an elevation in pressure in the left atrium. In addition to diastolic heart failure, a number of other medical conditions, including systolic dysfunction of the left ventricle and valve disease, can lead to elevated pressures in the left atrium. Increased left atrial pressure often causes acute or chronic breathlessness amongst other problems. In addition, a variety of heart conditions can lead to “right heart failure”, which can result in enlargement of the liver (hepatomegaly), fluid accumulation in the abdomen (ascites) and/or swelling of the lower limbs.


In the past, strategies have been described for the relief of high pressure in the right atrium, such as the creation of hole(s) in the native or surgically created septum between the left and right atria. These have been designed for the rare conditions of pulmonary hypertension or cavopulmonary connections for certain complex congenital heart diseases. O'Loughlin et al. recently described a fenestrated atrial septal defect closure device for the palliation of advanced pulmonary hypertension. However, this device allows bidirectional flow, and the passage of thrombi, and was shown to be closed over within 6 months of insertion. Thus a need still exists for devices to relieve high pressure in the left atrium and which will prevent or minimize the chance of the passage of thrombi.


Accordingly, there exists a need for devices and methods to treat heart failure particularly diastolic and/or systolic failure of the left ventricle and its consequences.


SUMMARY OF THE INVENTION

According to a first aspect of the invention, there is provided a device for treating heart failure in a patient, the device comprising:


a body;


at least one passage through the body;


at least one one way valve in the passage; and


a mounting means adapted for mounting the body in an opening provided in the patient's atrial septum,


wherein, in use, the device is oriented such that, when the patient's left atrial pressure exceeds the patient's right atrial pressure by a predetermined amount, the one way valve(s) opens to allow blood flow through the passage(s) from the left atrium to the right atrium to thereby reduce the left atrial pressure.


According to a second aspect of the invention, there is provided a device for treating heart failure or pulmonary venous hypertension in a patient, the device comprising:


a body;


at least one passage through the body;


at least one one way valve in the passage; and


a mounting means adapted for mounting the body in the patient's venous system,


wherein, in use, the device is oriented such that the one way valve(s) prevents blood flow through the passage(s) in a direction opposite to that of the natural flow direction.


The device is preferably adapted to be fitted into a blood vessel in the patient's venous system, such as the inferior vena cava, superior vena cava, the hepatic vein, an iliac vein, or one or more pulmonary veins.


According to a third aspect of the invention, there is provided a device for treating lower limb venous hypertension in a patient, the device comprising:


a body;


at least one passage through the body;


at least one one way valve in the passage; and


a mounting means adapted for mounting the body in the patient's lower limb venous system,


wherein, in use, the device is oriented such that the one way valve(s) prevents blood flow through the passage(s) in a direction opposite to that of the natural flow direction.


The above device is also suitable for treating varicose veins.


The body is preferably in the form of a stent, most preferably an expandable stent.


The valve is preferably a duckbill valve, a leaflet valve, a flap valve, a disc in cage type valve or a ball in cage type valve. The valve is preferably biased to a closed position, most preferably by the inherent resilience of the valve material. The valve preferably opens when the predetermined amount of pressure differential is at least approximately 2 mm Hg, preferably approximately 5 to 25 mm Hg, even more preferably 5 to 15 mm Hg.


In one form, the device has a single passage through the body, most preferably centrally located in relation to the body. In another form, the device has a single passage through the body, most preferably eccentrically located in relation to the body. In yet another form, the device has a plurality of passages through the body, each with a one way valve therein, most preferably each eccentrically located in relation to centre of the body.


According to a fourth aspect of the invention, there is provided a device for treating heart failure in a patient, the device comprising:


a body;


at least one passage through the body;


a mesh or grill arrangement within the passage and having apertures therein of a size permitting flow of blood, whilst substantially excluding thrombi, therethrough;


a mounting means adapted for mounting the body in an opening provided in the patient's atrial septum,


wherein, in use, the device allows blood flow through the passage(s) from the left atrium to the right atrium when the patient's left atrial pressure exceeds the patient's right atrial pressure to thereby reduce the patient's left atrial pressure.


The device preferably includes a mesh or grill arrangement across one or both ends of the passage(s).


The apertures preferably have a maximum dimension of less than 4 mm, most preferably less than 2 mm. The mesh or grill is preferably coated or impregnated with one or more drugs, adapted for preventing thrombosis or endothelialisation of the opening in the patient's atrial septum, including an anticoagulant substance, such as heparin, or an inhibitor of re-endothelialisation, such as sirolimus or paclitaxel.


In one form, the device has a single passage through the body, most preferably centrally located in relation to the body. In another form, the device has a plurality of passages through the body, each with a mesh or grill arrangement therein, most preferably each eccentrically located in relation to centre of the body.


The device is preferably flexible, most preferably formed from a material which can be deformed but later return to its original shape. An example of such a material is Nitinol.


The device is preferably collapsible and adapted for implanting via a catheter, although it could be inserted at surgery.


The device is preferably collapsible to a size able to pass through an opening made in the patient's atrial septum (or an enlargement of a pre-existing communication, by standard methods) and adapted to return to a shape where at least some of the device would have been unable to pass through the opening in the patient's atrial septum. The device is preferably formed from a Nitinol mesh, or any other material which can be deformed but later return to its original shape.


The mounting means preferably comprises at least one flange having a dimension larger than the opening in the patient's septum. More preferably, the mounting means preferably comprises a pair of spaced apart flanges having a dimension larger than the opening in the patient's septum.


The external dimension of the body, remote the flange(s), is preferably substantially equal to the opening in the patient's atrial septum.


In one embodiment, the flanges are adapted for gluing, suturing, stapling or pinning to the patient's septum.


In another embodiment, the flanges are spaced apart by about the thickness of the patient's atrial septum and are adapted to locate, most preferably by gripping, the patient's atrial septum therebetween.


According to a fifth aspect of the invention, there is provided a method for treating heart failure in a patient, the method comprising the steps of:


forming an opening in the patient's atrial septum;


inserting at least one one way valve in the opening that is oriented such that the one way valve(s) allows blood flow through the passage from the left atrium to the right atrium when the patient's left atrial pressure exceeds the patient's right atrial pressure; and


securing the one way valve(s) relative to the patient's atrial septum,


whereby, when the patient's left atrial pressure exceeds the patient's right atrial pressure by a predetermined amount, the valve opens to allow blood flow through the passage(s) from the left atrium to the right atrium to thereby reduce the patient's left atrial pressure.


The above method is particularly suited for treating cardiovascular disease manifest by left atrial hypertension, such as that due to left ventricular systolic or diastolic dysfunction.


The predetermined amount of pressure differential is at preferably least approximately 3 mm Hg, preferably approximately 5 to 25 mm Hg, even more preferably 5 to 15 mm Hg.


According to a sixth aspect of the invention, there is provided a method for treating heart failure in a patient, the method comprising the steps of:


forming an opening in the patient's atrial septum;


inserting a mesh or grill arrangement within the opening having apertures therein of a size permitting passage of blood, whilst substantially excluding passage of thrombi, therethrough; and


securing the mesh or grill arrangement relative to the patient's atrial septum.


The mesh or grill arrangement is preferably provided within a passage in a body, and the method preferably includes the step of securing the body relative to the patient's atrial septum.


The above method is particularly suited for treating cardiovascular disease manifest by left atrial hypertension, such as that due to left ventricular systolic or diastolic dysfunction.


According to a seventh aspect of the invention, there is provided a method for treating heart failure in a patient, the method comprising the steps of:


inserting at least one one way valve in the patient's venous system that is oriented such that the one way valve(s) prevents blood flow through the said venous system in a direction opposite to that of the natural flow direction; and


securing the one way valve(s) relative to the patient's venous system.


The method preferably includes the steps of inserting and securing the one way valve in the patient's blood vessel, such as the inferior vena cava, superior vena cava, the hepatic vein, an iliac vein, or one or more pulmonary veins.


The method preferably includes a step of inserting and securing, most preferably by expanding, a stent with the one way valve(s) therein.


According to an eighth aspect of the invention, there is provided a device for treating heart failure in a patient, the device comprising:


a tube having first and second ends in fluid communication with the left and right atriums of the heart respectively; and


a valve between the first and second ends and adapted to selectively prevent or allow fluid flow through the tube,


wherein, in use, when the patient's left atrial pressure exceeds the patient's right atrial pressure by a predetermined amount, the valve opens to allow blood flow through the tube from the left atrium to the right atrium to thereby reduce the left atrial pressure.


The valve opens when the predetermined amount of pressure differential is at preferably least approximately 2 mm Hg, preferably approximately 5 to 25 mm Hg, even more preferably approximately 5 to 15 mm Hg.


According to an ninth aspect of the invention, there is provided a device for treating heart failure or pulmonary venous hypertension in a patient, the device comprising:


a tube having first and second ends in fluid communication with the left and right atriums of the heart respectively; and


a one way valve in the tube,


wherein, in use, the one way valve prevents blood flow through the tube from the right atrium to the left atrium.


According to a tenth aspect of the invention, there is provided a method for treating heart failure in a patient, the method comprising the steps of:


connecting a tube externally between the patient's left and right atriums; and


inserting a one way valve in the tube that is oriented such that the one way valve allows blood flow through the passage from the left atrium to the right atrium when the patient's left atrial pressure exceeds the patient's right atrial pressure,


whereby, when the patient's left atrial pressure exceeds the patient's right atrial pressure, by a predetermined amount, the valve open to allow blood flow through the passage(s) from the left atrium to the right atrium to thereby reduce the patient's left atrial pressure.


The predetermined amount of pressure differential is at preferably least approximately 2 mm Hg, preferably approximately 5 to 25 mm Hg, even more preferably approximately 5 to 15 mm Hg.





BRIEF DESCRIPTION OF THE DRAWINGS

Preferred embodiments of the invention will now be described, by way of examples only, with reference to the accompanying drawings in which:



FIG. 1 is a front view of a first embodiment of a device for treating heart failure;



FIG. 2 is a cross sectional side view of the device shown in FIG. 1;



FIG. 3 is a cross sectional side view of the device shown in FIGS. 1 and 2 implanted in a human heart;



FIG. 4 is a rear view of the device shown in FIG. 1;



FIG. 5 is a front view of a second embodiment of a device for treating heart failure;



FIG. 6 is a front view of a third embodiment of a device to treat heart failure;



FIG. 7 is a cross sectional side view of the device shown in FIG. 6;



FIG. 8 is a front view of a fourth embodiment of a device to treat heart failure;



FIG. 9 is a cross sectional side view of the device shown in FIG. 8;



FIG. 10 is a cross sectional side view of a fifth embodiment of a device for treating heart failure;



FIG. 11 is a cross sectional side view of the device shown in FIG. 10 implanted in a patient's inferior vena cava;



FIG. 12 is a cross sectional side view of a first embodiment of a delivery mechanism for the device shown in FIG. 10;



FIG. 13 is a cross sectional side view of a second embodiment of a delivery mechanism for the device shown in FIG. 10;



FIG. 14 is a cross sectional side view of a sixth embodiment of a device for treating heart failure implanted in a patient's hepatic vein;



FIG. 15 is a cross sectional side view of a pair of the devices shown in FIG. 14 implanted in a patient's iliac veins;



FIG. 16 is a front view of a seventh embodiment of a device for treating heart failure;



FIG. 17 is a front view of an eighth embodiment of a device for treating heart failure;



FIG. 18 is a cross sectional side view of the device shown in FIG. 17;



FIG. 19a is a front view of a ninth embodiment of a device for treating heart failure;



FIG. 19b is a cross sectional side view the device shown in FIG. 19a;



FIG. 20 is a front view of a tenth embodiment of a device for treating heart failure,



FIG. 21a is a cross sectional side view of an eleventh embodiment of a device for treating heart failure, collapsed within a catheter;



FIG. 21b is a cross sectional perspective view of the device shown in FIG. 21a, collapsed within a catheter;



FIG. 22a is a cross sectional side view of the device shown in FIG. 21a, partially deployed from the catheter;



FIG. 22b is a cross sectional perspective view of the device shown in FIG. 21a, partially deployed from the catheter;



FIG. 22c is an enlarged, partial cross sectional side view of the device shown in FIG. 21a, partially deployed from the catheter;



FIG. 23a is a side view of the device shown in FIG. 21a, deployed from the catheter;



FIG. 23b is a cross sectional side view of the device shown in FIG. 21a, deployed from the catheter; and



FIG. 24 is a cross sectional side view of a twelfth embodiment of a device for treating heart failure.





DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS


FIGS. 1 to 4 show a first embodiment of a device 10 for treating heart failure. The device 10 includes a generally cylindrical body 12 with a mounting means, in the form of a pair of annular flanges 14 at either end with an annular gap 16 therebetween. The body 12 has a centrally located passage or duct 18 within which is provided a one way valve 20, in the form of three flexible valve leaflets 20a to 20c.


The external diameters of the body 12, the flanges 14 and internal diameter of the passage 18 are approximately 18, 38 and 12 mm respectively. In other embodiments (not shown), the diameter of the body 12 ranges from 8 to 25 mm, the diameter of the flanges 14 ranges from 20 to 50 mm, and the diameter of the passage 18 ranges from 4 to 15 mm.



FIG. 3 shows a patient's heart 22 with a left atrium 24 and a right atrium 26 separated by an atrial septum 28. The device 10 is mounted within a generally circular opening 30 made in the septum 28 and with the edges of the septum 28 adjacent the opening 30 positioned in the gap 16 between the flanges 14. The opening 30 has an internal diameter approximately equal to the external diameter of the body 12. The device 10 is retained adjacent the opening 30 in the septum 28 as the flanges 14 are larger, and thus cannot pass through, the opening 30. Alternatively, or in addition, one or both of the flanges 14 can be glued, sutured, stapled or pinned to the patient's septum 28 to secure the device 10 thereto.


The device 10 can be implanted during open heart surgery or percutaneously using a catheter. In either case, the opening 30 is firstly fashioned in the patient's atrial septum 28. Some or all of the device 10 is then collapsed to a size able to pass through the opening 30 and subsequently expanded to the configuration shown in FIG. 3. Forming the s body 12 and the flanges 14 of the device 10 from a Nitinol wire mesh result in it being suitable for implanting in a manner similar to the implanting of the AMPLATZER (Trade Mark) septal occluder produced by AGA Medical Corp. More particularly, the exterior faces of the flanges 14 are pulled away from one another which causes the device 10 to lengthen and simultaneously reduce in diameter for fitting within a catheter able to pass through the opening 30. When the separating force is then removed the flanges 14 return to the (expanded) configuration in FIGS. 1 to 4.


The device 10 is orientated during implanting with the one way valve 20 only allowing blood flow through the passage 18 from the left atrium 24 to the right atrium 26, as indicated by arrows 32. More particularly, when the left atrial pressure exceeds the right atrial pressure by about 5-15 mm Hg, the valve leaflets 20a to c separate and thus open the passage 18 to blood flow from the left atrium 24 to the right atrium 26.


The leaflets 20a to 20c are formed from biological, mechanical or engineered tissue and are inherently biased towards a closed position. Further, the patient's right atrial pressure exceeding the left atrial pressure also assists in the closing, and the maintaining closed, of the valve 20.


The relief and/or avoidance of the left atrial pressure significantly exceeding the right atrial pressure is beneficial in alleviating the adverse consequences of left atrial hypertension complicating cardiovascular diseases, including left ventricular systolic and/or diastolic dysfunction and/or valvular diseases.


As best seen in FIG. 4, the device 10 includes four thin collapsible struts 34 connected to a central fixture or boss 36 having an internally threaded opening. A cable (not shown) is threadedly attachable to the fixture 36. The fixture 36 is accessible from the left atrium.


To implant the device 10, it is firstly collapsed inside a catheter. When the catheter is correctly positioned adjacent the opening 30, the cable is used to push the device 10 out of the catheter, whereafter it expands to the shape shown in FIG. 3. The cable is then unscrewed from the fixture 36 and removed from the patient with the catheter.


The device 10 can also be adapted to allow later removal by a percutaneous route, for example by the placement of small hooks (not shown) on a surface of the device 10 that is closest to a nearby venous access site.



FIG. 5 shows a second embodiment of a device 40 for treating heart failure. The construction, function and implanting of the device 40 is similar to that of the device 10 and like reference numerals are used to indicate like features between the two embodiments. However, the device 40 has four eccentrically located passages 18 through the body 12 and blood flow therethrough is controlled by four corresponding sets of valve leaflets 20.



FIGS. 6 and 7 show a third embodiment of a device 50 for treating heart failure. The construction, operation and implantation of the device 50 is similar to that of the device 10 and like reference numerals are used to indicate like features between the two embodiments. However, the device 50 has only one collapsible strut 34 connected to a central fixture 36, to which a cable 52 can be attached. The fixture 36 is also accessible from the left atrium. In a variation of this embodiment, the fixture is accessible from the right atrium.



FIGS. 8 and 9 show a fourth embodiment of a device 60 for treating heart failure. The construction, function and implanting of the device 60 is similar to that of the device 10 and like reference numerals are used to indicate like features between the two embodiments. However, the device 60 has three fixtures 36 attached to the body 12, adjacent the passage 18, to which three respective cables 62 (see FIG. 9) can be attached. The fixtures 36 are accessible from the right atrium.



FIGS. 10 and 11 show a fifth embodiment of a device 70 for treating heart failure, in a manner similar to that of the device 10. However, unlike the earlier embodiments, the device 70 only has a single mounting flange 14 which, as shown in FIG. 11, makes it suitable for implanting in the inferior vena cava 72 at or near the junction with the right atrium 74. The device 70 is preferably produced from a deformable material that can resume its preformed shape (such as Nitinol) and may be implanted by a percutaneous approach.


More particularly, the device 70 is collapsed and introduced in the venous system within a sheath, and removed from the sheath to expand when correctly positioned.



FIGS. 12 and 13 show two mechanisms suitable for delivering the device 70 to the inferior vena cava. The mechanism shown in FIG. 12 is similar to that shown in FIGS. 6 and 7 and the mechanism shown in FIG. 13 is similar to that shown in FIGS. 8 and 9.



FIG. 14 is a cross sectional side view of a sixth embodiment of a device 80 for treating heart failure, implanted in a patient's hepatic vein 82. The device 80 does not include any mounting flanges and its body is instead an expandable stent 84 with a one way valve 20 therein.



FIG. 15 shows an alternative implanting of the device 80 in a patient's iliac veins 84 and 86.


The device 80 is also suitable for placement in the venous system of the lower limb or iliac system to relieve the signs or symptoms of lower limb hypertension (e.g., peripheral oedema and/or varicose veins).



FIG. 16 shows a seventh embodiment of a device 90 for treating heart failure. The construction, function and implanting of the device 90 is similar to that of the device 40 and like reference numerals are used to indicate like features between the two embodiments. However, the device 90 has only two eccentrically located passages 18 through the body 12 and blood flow therethrough is controlled by two corresponding sets of valve leaflets 20.



FIG. 17 shows an eighth embodiment of a device 100 for treating heart failure. This embodiment is constructed and implanted in a similar manner to that previously described. However, the device 100 has a passage 18 therethrough with a mesh or grill arrangement 102 across each end of the passage 18. The mesh 102 has apertures 104 therein of a maximum dimension of less than 4 mm which permit the flow of blood from the left to the right atrium through the passage 18, whilst substantially excluding thrombi. The mesh 102 is coated or impregnated with one or more drugs, adapted for preventing thrombosis or endothelialisation of the opening in the patient's atrial septum, including an anticoagulant substance, such as heparin, or an inhibitor of re-endothelialisation, such as sirolimus or paclitaxel.



FIGS. 19a and 19b show a ninth embodiment of a device 110 for treating heart failure. The construction, operation and implantation of the device 110 is similar to that of the device 10 and like reference numerals are used to indicate like features between the two embodiments. The device 110 utilizes a strut/fixture arrangement similar to that shown in FIGS. 6 and 7.



FIG. 20 shows a tenth embodiment of a device 130 for treating heart failure. The construction, operation and implantation of the device 130 is similar to that of the device 10 and like reference numerals are used to indicate like features between the two embodiments. The device 130 has a helical groove 132 for releasably engaging a corresponding fitting on the end of a catheter cable during implantation.



FIGS. 21a to 23b show an eleventh embodiment of a device 140 for treating heart failure. The construction, operation and implantation of the device 100 is similar to that of the device 10 and like reference numerals are used to indicate like features between the two embodiments. The body 12 and the flanges 14 of the device 140 are formed from a Nitinol wire mesh which result in it being suitable for implanting in a manner similar to the implanting of the AMPLATZER (Trade Mark) septal occluder produced by AGA Medical Corp. The device 140 is collapsed by pulling the exterior faces of the flanges 14 away from one another which causes the device 140 to lengthen and simultaneously reduce in diameter. When the separating force is removed the flanges 14 return to the (expanded) configuration.


More particularly, as shown in FIGS. 21a and 21b, the device 140 is initially collapsed within a catheter 142 of about 5 mm in diameter, which is able to pass through an opening in the septum. As shown in FIGS. 22a to 22c, the device 140 is then partially deployed from the catheter 142 by movement of wire 144, and thus head 146, relative to the catheter 142. This results in part of the device 140 expanding to form the first flange 14.


As shown in FIGS. 23a and 23b, fall deployment of the device 140 by further relative movement of the wire 144 and the head 146, relative to the catheter 142, results in the remainder of the device 140 expanding to form the second flange 14. The device 140 is initially attached to the head 146 by three pins 148, which are remotely released after the device has been deployed from the catheter 142.


In other similar embodiments (not shown) the catheter 142 has a diameter of 4-6 mm and the device 140 is initially attached to the head 146 by one or two releasable pins 148.



FIG. 20 shows a twelfth embodiment of a device 150 for treating heart failure. In this embodiment, a tube 152 of about 8 mm internal diameter provides an external fluid communication path between the heart's left and right atriums 154 and 156 respectively. A valve 158 is adapted to selectively occlude the tube 152. As with earlier embodiments, when the left atrial pressure exceeds the right atrial pressure by about 5-15 mm Hg, the valve 158 is released to open the interior of the tube 152 and allow blood flow from the left atrium 24 to the right atrium 26. In a variation of this embodiment, the valve 158 is a one way valve that prevents blood flow from the right atrium 156 to the left atrium 154.


Although the invention has been described with reference to the specific examples it will be appreciated by those skilled in the art that the invention may be embodied in many other forms.

Claims
  • 1. A device for treating a heart condition in a patient, the device comprising: a Nitinol mesh body adapted and configured to self-expand from a radially collapsed configuration to an expanded configuration, the body in its expanded configuration comprising a first flange and a second flange, each of the first and second flanges having an exterior face and an interior face, the body further comprising a central portion extending between the first and second flanges, the interior faces of the first and second flanges defining an annular gap surrounding the central portion, the interior faces of each of the first and second flanges having diameters that gradually increase with distance from the central portion of the body toward their respective exterior faces, the exterior faces of the first and second flanges having diameters that decrease with distance from their respective interior faces,wherein the body has a centrally located passage having a diameter of about 4-15 mm extending through the first and second flanges and the central portion,the body being configured to be delivered percutaneously to a patient's heart in the radially collapsed condition in which the exterior faces of the first and second flanges are separated, thereby causing the device to lengthen and reduce in diameter, and to self-expand to the expanded configuration in an opening in a septum of the heart to dispose the first flange in the left atrium, the second flange in the right atrium and the central portion of the body in the opening to permit blood to flow from the left atrium to the right atrium.
  • 2. The device of claim 1, wherein the device in its collapsed configuration is adapted to fit within a 4-6 mm diameter catheter.
  • 3. The device of claim 1, further comprising a proximal connector extending proximally from the exterior face of the first flange and adapted to be releasably connected to a delivery device within a catheter.
Priority Claims (1)
Number Date Country Kind
2006906202 Nov 2006 AU national
CROSS REFERENCE TO RELATED APPLICATIONS

This application is a continuation of pending U.S. application Ser. No. 12/447,617, filed Apr. 28, 2009, which is the national phase filing of International Application No. PCT/AU2007/001704, filed Nov. 7, 2007, which application claims priority to Australian Application No. 2006906202, filed Nov. 7, 2006, each of which is herein incorporated by reference in its entirety.

US Referenced Citations (364)
Number Name Date Kind
3837345 Matar Sep 1974 A
3874388 King et al. Apr 1975 A
4018228 Goosen Apr 1977 A
4373216 Klawitter Feb 1983 A
4491986 Gabbay Jan 1985 A
4655217 Reed Apr 1987 A
4705507 Boyles Nov 1987 A
5100423 Fearnot Mar 1992 A
5108420 Marks Apr 1992 A
5171233 Amplatz et al. Dec 1992 A
5284488 Sideris Feb 1994 A
5332402 Teitelbaum Jul 1994 A
5334217 Das Aug 1994 A
5387219 Rapper Feb 1995 A
5413599 Imachi et al. May 1995 A
5429144 Wilk Jul 1995 A
5433727 Sideris Jul 1995 A
5464449 Ryan et al. Nov 1995 A
5478353 Yoon Dec 1995 A
5488958 Topel et al. Feb 1996 A
5556386 Todd Sep 1996 A
5556408 Farhat Sep 1996 A
5599295 Rosen et al. Feb 1997 A
5672153 Lax et al. Sep 1997 A
5693090 Unsworth et al. Dec 1997 A
5702412 Popov et al. Dec 1997 A
5725552 Kotula et al. Mar 1998 A
5741297 Simon Apr 1998 A
5824071 Nelson et al. Oct 1998 A
5846261 Kotula et al. Dec 1998 A
5876436 Vanney et al. Mar 1999 A
5893369 Lemole Apr 1999 A
5911725 Boury et al. Jun 1999 A
5916214 Cosio et al. Jun 1999 A
5944738 Amplatz et al. Aug 1999 A
5964754 Osypka Oct 1999 A
6016452 Kasevich Jan 2000 A
6050936 Schweich et al. Apr 2000 A
6056744 Edwards May 2000 A
6059827 Fenton May 2000 A
6068635 Gianotti May 2000 A
6077257 Edwards et al. Jun 2000 A
6120534 Ruiz Sep 2000 A
6123682 Knudson et al. Sep 2000 A
6123715 Amplatz Sep 2000 A
6152937 Peterson et al. Nov 2000 A
6156055 Ravenscroft Dec 2000 A
6168622 Mazzocchi Jan 2001 B1
6190353 Makower et al. Feb 2001 B1
6193734 Bolduc et al. Feb 2001 B1
6210338 Afremov et al. Apr 2001 B1
6214029 Thill et al. Apr 2001 B1
6241678 Afremov et al. Jun 2001 B1
6258119 Hussein et al. Jul 2001 B1
6283983 Makower et al. Sep 2001 B1
6286512 Loeb et al. Sep 2001 B1
6334864 Amplatz et al. Jan 2002 B1
6350277 Kocur Feb 2002 B1
6355052 Neuss et al. Mar 2002 B1
6355056 Pinheiro Mar 2002 B1
6357735 Haverinen Mar 2002 B2
6383195 Richard May 2002 B1
6391036 Berg et al. May 2002 B1
6395017 Dwyer et al. May 2002 B1
6402777 Globerman et al. Jun 2002 B1
6409716 Sahatjian et al. Jun 2002 B1
6440152 Gainor et al. Aug 2002 B1
6454795 Chuter Sep 2002 B1
6458153 Bailey et al. Oct 2002 B1
6468301 Amplatz et al. Oct 2002 B1
6468303 Amplatz et al. Oct 2002 B1
6527746 Oslund et al. Mar 2003 B1
6572652 Shaknovich Jun 2003 B2
6579311 Makower Jun 2003 B1
6599308 Amplatz Jul 2003 B2
6626936 Stinson Sep 2003 B2
6638257 Amplatz Oct 2003 B2
6645143 Vantassel et al. Nov 2003 B2
6666885 Moe Dec 2003 B2
6695877 Brucker et al. Feb 2004 B2
6699256 Logan et al. Mar 2004 B1
6712836 Berg et al. Mar 2004 B1
6719768 Cole et al. Apr 2004 B1
6719934 Stinson Apr 2004 B2
6837901 Rabkin et al. Jan 2005 B2
6866679 Kusleika Mar 2005 B2
6911037 Gainor et al. Jun 2005 B2
6913614 Marino et al. Jul 2005 B2
6932837 Amplatz et al. Aug 2005 B2
6936058 Forde et al. Aug 2005 B2
6979343 Russo et al. Dec 2005 B2
7033372 Cahalan Apr 2006 B1
7037329 Martin May 2006 B2
7044134 Khairkhahan et al. May 2006 B2
7097653 Freudenthal et al. Aug 2006 B2
7105024 Richelsoph Sep 2006 B2
7144410 Marino et al. Dec 2006 B2
7226466 Opolski Jun 2007 B2
7309341 Ortiz et al. Dec 2007 B2
7317951 Schneider et al. Jan 2008 B2
7338514 Wahr et al. Mar 2008 B2
7350995 Rhodes Apr 2008 B1
7419498 Opolski et al. Sep 2008 B2
7445630 Lashinski et al. Nov 2008 B2
7473266 Glaser Jan 2009 B2
7485141 Majercak et al. Feb 2009 B2
7530995 Quijano et al. May 2009 B2
7611534 Kapadia et al. Nov 2009 B2
7625392 Coleman et al. Dec 2009 B2
7658747 Forde et al. Feb 2010 B2
7678123 Chanduszko Mar 2010 B2
7691144 Chang et al. Apr 2010 B2
7699297 Cicenas et al. Apr 2010 B2
7704268 Chanduszko Apr 2010 B2
7722629 Chambers May 2010 B2
7758589 Ortiz et al. Jul 2010 B2
7842026 Cahill et al. Nov 2010 B2
7860579 Goetzinger et al. Dec 2010 B2
7871419 Devellian et al. Jan 2011 B2
7905901 Corcoran et al. Mar 2011 B2
7967769 Faul et al. Jun 2011 B2
7976564 Blaeser et al. Jul 2011 B2
8010186 Ryu Aug 2011 B1
8021359 Auth et al. Sep 2011 B2
8034061 Amplatz et al. Oct 2011 B2
8043360 McNamara et al. Oct 2011 B2
8048147 Adams Nov 2011 B2
8052750 Tuval et al. Nov 2011 B2
8157860 McNamara et al. Apr 2012 B2
8172896 McNamara et al. May 2012 B2
8216256 Raschdorf et al. Jul 2012 B2
8252042 McNamara et al. Aug 2012 B2
8303623 Melzer et al. Nov 2012 B2
8313505 Amplatz et al. Nov 2012 B2
8361138 Adams Jan 2013 B2
8398670 Amplatz et al. Mar 2013 B2
8460372 McNamara et al. Jun 2013 B2
8740962 Finch et al. Jun 2014 B2
8745845 Finch et al. Jun 2014 B2
8752258 Finch et al. Jun 2014 B2
8777974 Amplatz et al. Jul 2014 B2
8778008 Amplatz et al. Jul 2014 B2
8864822 Spence et al. Oct 2014 B2
8882697 Celermajer et al. Nov 2014 B2
8951223 McNamara et al. Feb 2015 B2
8979923 Spence et al. Mar 2015 B2
9005155 Sugimoto Apr 2015 B2
9205236 McNamara et al. Dec 2015 B2
9232997 Sugimoto et al. Jan 2016 B2
9277995 Celermajer et al. Mar 2016 B2
9358371 McNamara et al. Jun 2016 B2
9456812 Finch et al. Oct 2016 B2
9642993 McNamara et al. May 2017 B2
9649480 Sugimoto et al. May 2017 B2
9681948 Levi et al. Jun 2017 B2
9724499 Rottenberg et al. Aug 2017 B2
9757107 McNamara et al. Sep 2017 B2
9775636 Fazio et al. Oct 2017 B2
9937036 Sugimoto et al. Apr 2018 B2
10045766 McNamara et al. Aug 2018 B2
10188375 McNamara et al. Jan 2019 B2
10398421 Celermajer et al. Sep 2019 B2
10413284 McNamara et al. Sep 2019 B2
10413286 McNamara et al. Sep 2019 B2
10463477 Forcucci et al. Nov 2019 B2
10568751 McNamara Feb 2020 B2
10588611 Magin et al. Mar 2020 B2
10610210 Finch et al. Apr 2020 B2
10624621 Celermajer Apr 2020 B2
10632292 Forcucci et al. Apr 2020 B2
10675450 Finch Jun 2020 B2
20010027287 Shmulewitz et al. Oct 2001 A1
20010029368 Berube Oct 2001 A1
20010053932 Phelps et al. Dec 2001 A1
20020033180 Solem Mar 2002 A1
20020077698 Peredo Jun 2002 A1
20020082525 Oslund et al. Jun 2002 A1
20020082613 Hathaway et al. Jun 2002 A1
20020087208 Kobiish et al. Jul 2002 A1
20020095172 Mazzocchi et al. Jul 2002 A1
20020120277 Hauschild et al. Aug 2002 A1
20020133148 Daniel et al. Sep 2002 A1
20020143289 Ellis et al. Oct 2002 A1
20020161424 Rapacki et al. Oct 2002 A1
20020161432 Mazzucco et al. Oct 2002 A1
20020165606 Wolf et al. Nov 2002 A1
20020169377 Khairkhahan et al. Nov 2002 A1
20020173742 Keren et al. Nov 2002 A1
20020177894 Acosta et al. Nov 2002 A1
20020183786 Girton Dec 2002 A1
20020183826 Dorn et al. Dec 2002 A1
20030009165 Edwards et al. Jan 2003 A1
20030032967 Park et al. Feb 2003 A1
20030055455 Yang et al. Mar 2003 A1
20030093072 Friedman May 2003 A1
20030125798 Martin Jul 2003 A1
20040044351 Searle Mar 2004 A1
20040078950 Schreck Apr 2004 A1
20040087937 Eggers et al. May 2004 A1
20040093075 Kuehne May 2004 A1
20040102719 Keith et al. May 2004 A1
20040102797 Golden et al. May 2004 A1
20040111095 Gordon et al. Jun 2004 A1
20040133236 Chanduszko Jul 2004 A1
20040143261 Hartley et al. Jul 2004 A1
20040143262 Visram et al. Jul 2004 A1
20040143292 Marino et al. Jul 2004 A1
20040162514 Alferness et al. Aug 2004 A1
20040176788 Opolski Sep 2004 A1
20040193152 Sutton et al. Sep 2004 A1
20040193261 Berreklouw Sep 2004 A1
20040206363 McCarthy et al. Oct 2004 A1
20040220653 Borg et al. Nov 2004 A1
20040236308 Herweck et al. Nov 2004 A1
20040243143 Corcoran et al. Dec 2004 A1
20040267306 Blaeser et al. Dec 2004 A1
20050015953 Keidar Jan 2005 A1
20050049692 Numamoto et al. Mar 2005 A1
20050049697 Sievers Mar 2005 A1
20050065507 Hartley et al. Mar 2005 A1
20050065546 Corcoran et al. Mar 2005 A1
20050065548 Marino et al. Mar 2005 A1
20050070934 Tanaka et al. Mar 2005 A1
20050075655 Bumbalough et al. Apr 2005 A1
20050075665 Brenzel et al. Apr 2005 A1
20050080400 Corcoran et al. Apr 2005 A1
20050080430 Wright et al. Apr 2005 A1
20050096735 Hojeibane et al. May 2005 A1
20050113868 Devellian et al. May 2005 A1
20050131503 Solem Jun 2005 A1
20050137609 Guiraudon Jun 2005 A1
20050137686 Salahieh et al. Jun 2005 A1
20050148925 Rottenberg et al. Jul 2005 A1
20050159738 Visram et al. Jul 2005 A1
20050165344 Dobak Jul 2005 A1
20050187616 Realyvasquez Aug 2005 A1
20050222604 Schaeffer Oct 2005 A1
20050234537 Edin Oct 2005 A1
20050240205 Berg et al. Oct 2005 A1
20050251063 Basude Nov 2005 A1
20050251187 Beane et al. Nov 2005 A1
20050267524 Chanduszko Dec 2005 A1
20050273075 Krulevitch et al. Dec 2005 A1
20050273124 Chanduszko Dec 2005 A1
20050288722 Eigler et al. Dec 2005 A1
20060004323 Chang et al. Jan 2006 A1
20060009800 Christianson et al. Jan 2006 A1
20060009832 Fisher Jan 2006 A1
20060041183 Massen et al. Feb 2006 A1
20060052821 Abbott et al. Mar 2006 A1
20060085060 Campbell Apr 2006 A1
20060095066 Chang et al. May 2006 A1
20060111704 Brenneman et al. May 2006 A1
20060122646 Corcoran et al. Jun 2006 A1
20060122647 Callaghan et al. Jun 2006 A1
20060135990 Johnson Jun 2006 A1
20060136043 Cully et al. Jun 2006 A1
20060155305 Freudenthal et al. Jul 2006 A1
20060184088 Van Bibber et al. Aug 2006 A1
20060210605 Chang et al. Sep 2006 A1
20060217761 Opolski Sep 2006 A1
20060224153 Fischell et al. Oct 2006 A1
20060224183 Freudenthal Oct 2006 A1
20060241675 Johnson et al. Oct 2006 A1
20060241745 Solem Oct 2006 A1
20060247680 Amplatz et al. Nov 2006 A1
20060253184 Amplatz Nov 2006 A1
20060259121 Osypka Nov 2006 A1
20060265004 Callaghan et al. Nov 2006 A1
20060276882 Case et al. Dec 2006 A1
20070005127 Boekstegers et al. Jan 2007 A1
20070010851 Chanduszko et al. Jan 2007 A1
20070021739 Weber Jan 2007 A1
20070027528 Agnew Feb 2007 A1
20070038295 Case et al. Feb 2007 A1
20070043431 Melsheimer Feb 2007 A1
20070088375 Beane et al. Apr 2007 A1
20070088388 Opolski et al. Apr 2007 A1
20070118207 Amplatz et al. May 2007 A1
20070123934 Whisenant et al. May 2007 A1
20070129755 Abbott et al. Jun 2007 A1
20070168018 Amplatz et al. Jul 2007 A1
20070185513 Woolfson et al. Aug 2007 A1
20070197952 Stiger Aug 2007 A1
20070198060 Devellian et al. Aug 2007 A1
20070209957 Glenn et al. Sep 2007 A1
20070225759 Thommen et al. Sep 2007 A1
20070244517 Callaghan Oct 2007 A1
20070250115 Opoiski et al. Oct 2007 A1
20070265658 Nelson et al. Nov 2007 A1
20070270741 Hassett et al. Nov 2007 A1
20070282157 Rottenberg et al. Dec 2007 A1
20080015619 Figulla et al. Jan 2008 A1
20080033425 Davis et al. Feb 2008 A1
20080033478 Meng Feb 2008 A1
20080033543 Gurskis et al. Feb 2008 A1
20080039804 Edmiston et al. Feb 2008 A1
20080039881 Greenberg Feb 2008 A1
20080039922 Miles et al. Feb 2008 A1
20080058940 Wu et al. Mar 2008 A1
20080071135 Shaknovich Mar 2008 A1
20080086168 Cahill Apr 2008 A1
20080103508 Karakurum May 2008 A1
20080109069 Coleman et al. May 2008 A1
20080119891 Miles et al. May 2008 A1
20080125861 Webler et al. May 2008 A1
20080154250 Makower et al. Jun 2008 A1
20080154302 Opolski et al. Jun 2008 A1
20080154351 Leewood et al. Jun 2008 A1
20080154355 Benichou et al. Jun 2008 A1
20080161901 Heuser et al. Jul 2008 A1
20080172123 Yadin Jul 2008 A1
20080177381 Navia et al. Jul 2008 A1
20080183279 Bailey et al. Jul 2008 A1
20080188880 Fischer et al. Aug 2008 A1
20080188888 Adams et al. Aug 2008 A1
20080215008 Nance et al. Sep 2008 A1
20080221582 Gia et al. Sep 2008 A1
20080228264 Li et al. Sep 2008 A1
20080249397 Kapadia Oct 2008 A1
20080249562 Cahill Oct 2008 A1
20080249612 Osborne et al. Oct 2008 A1
20080262592 Jordan et al. Oct 2008 A1
20080269662 Vassiliades et al. Oct 2008 A1
20080312679 Hardert et al. Dec 2008 A1
20090018570 Righini et al. Jan 2009 A1
20090030495 Koch Jan 2009 A1
20090054805 Boyle Feb 2009 A1
20090054982 Cimino Feb 2009 A1
20090054984 Shortkroff et al. Feb 2009 A1
20090062841 Amplatz et al. Mar 2009 A1
20090076541 Chin et al. Mar 2009 A1
20090082803 Adams et al. Mar 2009 A1
20090099647 Glimsdale et al. Apr 2009 A1
20090112050 Farnan et al. Apr 2009 A1
20090112244 Freudenthal Apr 2009 A1
20090112251 Qian et al. Apr 2009 A1
20090177269 Kalmann et al. Jul 2009 A1
20090234443 Ottma et al. Sep 2009 A1
20100030259 Pavcnik et al. Feb 2010 A1
20100114140 Chanduszko May 2010 A1
20100131053 Agnew May 2010 A1
20100268316 Brenneman et al. Oct 2010 A1
20110004296 Lutter et al. Jan 2011 A1
20110040374 Goetz et al. Feb 2011 A1
20110106149 Ryan et al. May 2011 A1
20110130784 Kusleika Jun 2011 A1
20110213364 Davis et al. Sep 2011 A1
20110218479 Rottenberg et al. Sep 2011 A1
20110257723 McNamara Oct 2011 A1
20110295183 Finch et al. Dec 2011 A1
20120022639 Hacohen et al. Jan 2012 A1
20120290062 McNamara et al. Nov 2012 A1
20130178784 McNamara et al. Jul 2013 A1
20140277054 McNamara et al. Sep 2014 A1
20150039084 Levi et al. Feb 2015 A1
20150119796 Finch Apr 2015 A1
20160022423 McNamara et al. Jan 2016 A1
20160051800 Vassiliades et al. Feb 2016 A1
20160120550 McNamara et al. May 2016 A1
20180256865 Finch et al. Sep 2018 A1
20190021861 Finch Jan 2019 A1
20190269392 Celermajer et al. Sep 2019 A1
20190336163 McNamara et al. Nov 2019 A1
Foreign Referenced Citations (28)
Number Date Country
1218379 Jun 1999 CN
1556719 Dec 2004 CN
1582136 Feb 2005 CN
1780589 May 2006 CN
101035481 Sep 2007 CN
101035488 Sep 2007 CN
101292889 Oct 2008 CN
101426431 May 2009 CN
1264582 Feb 2002 EP
1480565 Sep 2003 EP
1470785 Oct 2004 EP
1849440 Oct 2007 EP
2827153 Jan 2003 FR
58-27935 Jun 1983 JP
H02-277459 Nov 1990 JP
2003530143 Oct 2003 JP
WO9527448 Oct 1995 WO
WO9808456 Mar 1998 WO
WO9842403 Oct 1998 WO
WO0115618 Mar 2001 WO
WO02094363 Nov 2002 WO
WO2004019811 Mar 2004 WO
WO2005048881 Jun 2005 WO
WO2005048883 Jun 2005 WO
WO2006127765 Nov 2006 WO
WO2007054116 May 2007 WO
WO2007083288 Jul 2007 WO
WO2008058940 May 2008 WO
Non-Patent Literature Citations (29)
Entry
U.S. Appl. No. 10/292,690, filed May 21, 2019, Celermajer et al.
Ad et al.; A one way valved atrial septal patch: A new surgical technique and its clinical application; The Journal of Thoracic and Cardiovascular Surgery; 111; pp. 841-848; Apr. 1996.
Althoff et al.; Long-term follow up of a fenestrated amplatzer atrial septal occluder in pulmonary arterial hypertension; Chest; 133(1); pp. 183-185; Jan. 2008.
Atz et al.; Preoperative management of pulmonary venous hypertension in hypoplastic left heart syndrome with restrictive atrial septal defect; the American Journal of Cardiology; 83; pp. 1224-1228; Apr. 15, 1999.
Bailey, Steven R.; Nanotechnology in prosthetic heart valves (presentation); 31 pgs.; (year of pub. sufficiently earlier than effective US filing date and any foreign priority date) 2005.
Bolling, Steven; Direct flow medical—My valve is better (presentation); 21 pgs.; Apr. 23, 2009.
Cheatham, John P.; Intervention in the critically ill neonate and infant with hypoplastic left heart syndrome and intact atrial septum; Journal of Interventional Cardiology; 14(3); pp. 357-366; Jun. 2001.
Coselli, Joseph S.; No! Valve replacement: Patient prosthetic mismatch rarely occurs (presentation); 75 pgs.; Apr. 25, 2009.
Design News; Low power piezo motion; retrieved from the internet (http://www.designnews.com/document.asp?doc_id=229053&dfpPParams=ht_13,aid_229053&dfpLayout=article); 3 pgs.; May 14, 2010.
Gaudiani et al.; A philosophical approach to mirral valve repair (presentation); 28 pgs.; Apr. 24, 2009.
Hijazi, Zayad M.; Valve implantation (presentation); 36 pgs.; May 10, 2007.
Larios et al.; The use of an artificial foraminal valve prosthesis in the closure of interatrial and interventricular septal defects; Chest; 36(6); pp. 631-641; Dec. 1959.
Leon, Martin B.; Transcatheter aortic valve therapy: Summary thoughts (presentation); 19 pgs.; Jun. 24, 2009.
Moses, Jeffrey W.; The good, the bad and the ugly of transcatheter AVR (presentation); 28 pgs.; Jul. 10, 2009.
O'Loughlin et al.; Insertion of a fenestrated amplatzer atrial sestosotomy device for severe pulmonary hypertension; Heart Lung Circ.; 15(4); pp. 275-277; Aug. 2006.
Park et al.; Blade atrial septostomy: Collaborative study; Circulation; 66(2); pp. 258-266; Aug. 1982.
Pedra et al.; Stent implantation to create interatrial communications in patients with complex congenital heart disease; Catheterization and Cardiovascular Interventions; 47; pp. 310-313; Jan. 27, 1999.
Perry et al.; Creation and maintenance of an adequate interatrial communication in left atrioventricular valve atresia or stenosis; The American Journal of Cardiology; 58; pp. 622-626; Sep. 15, 1986.
Philips et al.; Ventriculofemoroatrial shunt: A viable alternative for the treatment of hydrocephalus; J. Neurosurg.; 86; pp. 1063-1066; Jun. 1997.
Physik Instrumente; Piezo for Motion Control in Medical Design and Drug Research (product information); Physik Instrumente (PI) GmbH & Co. KG; 22 pgs.; © Nov. 21, 2010.
Roven et al.; Effect of compromising right ventricular function in left ventricular failure by means of interatrial and other shunts; Am J Cardiol.; 24(2); pp. 209-219; Aug. 1969.
Sambhi et al.; Pathologic Physiology of Lutembacher Syndrome; Am J Cardiol.; 2(6); pp. 681-686; Dec. 1958.
Sommer et al.; Transcatheter creation of atrial septai defect and fontan fenestration with “butterfly” stent technique; Journal of the American college of Cardiology; 33(2); Suppl. A; 3 pgs.; Feb. 1999.
Stone, Gregg W.; Transcatheter devices for mirral valve repair, surveying the landscape (presentation); 48 pgs.: Jul. 10, 2009.
Stormer et al.; Comparative study of in vitro flow characteristics between a human aortic valve and a designed aortic valve and six corresponding types of prosthetic heart valves; Eur Surg Res; 8(2); pp. 117-131; (year of pub. sufficiently earlier than effective US filing date and any foreign priority date) 1976.
Watterson et al.; Very small pulmonary arteries: Central end-to-side shunt; Ann. Thorac. Surg.; 52(5); pp. 1132-1137; Nov. 1991.
Celermajer et al.; U.S. Appl. No. 14/498,903 entitled “Apparatus and methods to create and maintain an intra-atrial pressure relief opening,” filed Sep. 26, 2014.
McNamara; U.S. Appl. No. 16/801,046 entitled “Devices and methods for coronary sinus pressure relief,” filed Feb. 25, 2020.
McNamara et al.; U.S. Appl. No. 17/454,019 entitled “Intra-atrial implants made of non-braided material,” filed Nov. 5, 2021.
Related Publications (1)
Number Date Country
20200245991 A1 Aug 2020 US
Continuations (1)
Number Date Country
Parent 12447617 US
Child 16854100 US